{"id":{"repo_id":"aachen","oai_identifier":"oai:publications.rwth-aachen.de:59347"},"canonical_url":"https://search.dev.ndltd.org/etd/aachen/oai:publications.rwth-aachen.de:59347","repository":{"repo_id":"aachen","name":"RWTH Aachen University","base_url":"https://publications.rwth-aachen.de/oai2d"},"display":{"title":"Zum Einfluß von Dialysemembranmaterialien auf den [beta]-2-Mikroglobulinspiegel unter Hämodialyse","abstract":"A serious late effect in the dialsysis treatment is the dialysis associated amyloidosis as a result of accumulation of beta2-M in the serum. Aim of this study was to examine if the beta2-M concentration in blood can be reduced by dialysator-membranes with different permeability and adsorption capacity. For this purpose the following experiments have been carried out: 1. Determination of beta2-M-Clearance during dialysis with cuprophane- and PMMA-membranes. 2. Reduction of beta2-M-concentration in 9 different high-flux- and low-flux-membranes during a dialysis treatment. 3. Observation of beta2-M-concentration during one year of dialysis treatment using 4 different membrane-types at 10 patients each. The experiments show that neither the low-flux-membrane cuprophane nor the low-flux-membrane polysulfone are able to remove beta2-M from the serum of patients. Synthetic high-flux-membranes like polysulfone, polyamid and polymethylmethacrylat (PMMA) however are able to reduce the beta2-M-level during dialysis but without reaching normal results. Among these the PMMA-membrane possibly has the best effects because of its adsorptive capacity. This is demonstrated best in the long-term treatment. With this membrane a clearance of ca. 39ml/min can be reached. Although there is an elimination by synthetic membranes the predialytic concentration of beta2-M in blood is only little lower compared with non-eliminating membranes. Non of the examined membranes is able to normalize the concentration of beta2-M in serum. Because of the small number of cases and the short time of observation it is not possible to give evidence if by a minimal improvement of the elimination of beta2-M by synthetic high-flux-membranes the genesis of dialysis-associated amyloidosis is slowed down or prevented.","abstract_html":"A serious late effect in the dialsysis treatment is the dialysis associated amyloidosis as a result of accumulation of beta2-M in the serum. Aim of this study was to examine if the beta2-M concentration in blood can be reduced by dialysator-membranes with different permeability and adsorption capacity. For this purpose the following experiments have been carried out: 1. Determination of beta2-M-Clearance during dialysis with cuprophane- and PMMA-membranes. 2. Reduction of beta2-M-concentration in 9 different high-flux- and low-flux-membranes during a dialysis treatment. 3. Observation of beta2-M-concentration during one year of dialysis treatment using 4 different membrane-types at 10 patients each. The experiments show that neither the low-flux-membrane cuprophane nor the low-flux-membrane polysulfone are able to remove beta2-M from the serum of patients. Synthetic high-flux-membranes like polysulfone, polyamid and polymethylmethacrylat (PMMA) however are able to reduce the beta2-M-level during dialysis but without reaching normal results. Among these the PMMA-membrane possibly has the best effects because of its adsorptive capacity. This is demonstrated best in the long-term treatment. With this membrane a clearance of ca. 39ml/min can be reached. Although there is an elimination by synthetic membranes the predialytic concentration of beta2-M in blood is only little lower compared with non-eliminating membranes. Non of the examined membranes is able to normalize the concentration of beta2-M in serum. Because of the small number of cases and the short time of observation it is not possible to give evidence if by a minimal improvement of the elimination of beta2-M by synthetic high-flux-membranes the genesis of dialysis-associated amyloidosis is slowed down or prevented.","abstract_has_math":false,"creators":["Koch, Antje"],"institution":"Publikationsserver der RWTH Aachen University","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Mann, Helmut"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2003,"date_issued":"2003","date_published":"2003","updated_at":"2026-07-30T19:42:39Z","subjects":["info:eu-repo/classification/ddc/610","Medizin","b2-Mikroglobulin","Amyloidose","Dialysemembranen","Hämodialyse"],"languages":["ger"],"rights":["info:eu-repo/semantics/openAccess"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-121142%22"],"render_values":[{"text":"https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-121142%22","href":"https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-121142%22","code":true}]}]},"links":{"outbound_url":"https://publications.rwth-aachen.de/record/59347","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Mann, Helmut"]},{"key":"dc:creator","label":"Author","values":["Koch, Antje"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:coverage","label":"Dc Coverage","values":["DE"]},{"key":"dc:date","label":"Dc Date","values":["2003"]},{"key":"dc:publisher","label":"Institution","values":["Publikationsserver der RWTH Aachen University"]},{"key":"dc:relation","label":"Dc Relation","values":["info:eu-repo/semantics/altIdentifier/urn/urn:nbn:de:hbz:82-opus-7616"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/doctoralThesis","info:eu-repo/semantics/publishedVersion"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["info:eu-repo/classification/ddc/610","Medizin","b2-Mikroglobulin","Amyloidose","Dialysemembranen","Hämodialyse"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["ger"]},{"key":"dc:rights","label":"Dc Rights","values":["info:eu-repo/semantics/openAccess"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://publications.rwth-aachen.de/record/59347","https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-121142%22"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["A serious late effect in the dialsysis treatment is the dialysis associated amyloidosis as a result of accumulation of beta2-M in the serum. Aim of this study was to examine if the beta2-M concentration in blood can be reduced by dialysator-membranes with different permeability and adsorption capacity. For this purpose the following experiments have been carried out: 1. Determination of beta2-M-Clearance during dialysis with cuprophane- and PMMA-membranes. 2. Reduction of beta2-M-concentration in 9 different high-flux- and low-flux-membranes during a dialysis treatment. 3. Observation of beta2-M-concentration during one year of dialysis treatment using 4 different membrane-types at 10 patients each. The experiments show that neither the low-flux-membrane cuprophane nor the low-flux-membrane polysulfone are able to remove beta2-M from the serum of patients. Synthetic high-flux-membranes like polysulfone, polyamid and polymethylmethacrylat (PMMA) however are able to reduce the beta2-M-level during dialysis but without reaching normal results. Among these the PMMA-membrane possibly has the best effects because of its adsorptive capacity. This is demonstrated best in the long-term treatment. With this membrane a clearance of ca. 39ml/min can be reached. Although there is an elimination by synthetic membranes the predialytic concentration of beta2-M in blood is only little lower compared with non-eliminating membranes. Non of the examined membranes is able to normalize the concentration of beta2-M in serum. Because of the small number of cases and the short time of observation it is not possible to give evidence if by a minimal improvement of the elimination of beta2-M by synthetic high-flux-membranes the genesis of dialysis-associated amyloidosis is slowed down or prevented."]},{"key":"dc:source","label":"Dc Source","values":["Aachen : Publikationsserver der RWTH Aachen University 83 S. : Ill., graph. Darst. (2003). = Aachen, Techn. Hochsch., Diss., 2003"]},{"key":"dc:title","label":"Title","values":["Zum Einfluß von Dialysemembranmaterialien auf den [beta]-2-Mikroglobulinspiegel unter Hämodialyse"]}]}],"canonical_facts":{"dc:contributor":["Mann, Helmut"],"dc:coverage":["DE"],"dc:creator":["Koch, Antje"],"dc:date":["2003"],"dc:description":["A serious late effect in the dialsysis treatment is the dialysis associated amyloidosis as a result of accumulation of beta2-M in the serum. Aim of this study was to examine if the beta2-M concentration in blood can be reduced by dialysator-membranes with different permeability and adsorption capacity. For this purpose the following experiments have been carried out: 1. Determination of beta2-M-Clearance during dialysis with cuprophane- and PMMA-membranes. 2. Reduction of beta2-M-concentration in 9 different high-flux- and low-flux-membranes during a dialysis treatment. 3. Observation of beta2-M-concentration during one year of dialysis treatment using 4 different membrane-types at 10 patients each. The experiments show that neither the low-flux-membrane cuprophane nor the low-flux-membrane polysulfone are able to remove beta2-M from the serum of patients. Synthetic high-flux-membranes like polysulfone, polyamid and polymethylmethacrylat (PMMA) however are able to reduce the beta2-M-level during dialysis but without reaching normal results. Among these the PMMA-membrane possibly has the best effects because of its adsorptive capacity. This is demonstrated best in the long-term treatment. With this membrane a clearance of ca. 39ml/min can be reached. Although there is an elimination by synthetic membranes the predialytic concentration of beta2-M in blood is only little lower compared with non-eliminating membranes. Non of the examined membranes is able to normalize the concentration of beta2-M in serum. Because of the small number of cases and the short time of observation it is not possible to give evidence if by a minimal improvement of the elimination of beta2-M by synthetic high-flux-membranes the genesis of dialysis-associated amyloidosis is slowed down or prevented."],"dc:identifier":["https://publications.rwth-aachen.de/record/59347","https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-121142%22"],"dc:language":["ger"],"dc:publisher":["Publikationsserver der RWTH Aachen University"],"dc:relation":["info:eu-repo/semantics/altIdentifier/urn/urn:nbn:de:hbz:82-opus-7616"],"dc:rights":["info:eu-repo/semantics/openAccess"],"dc:source":["Aachen : Publikationsserver der RWTH Aachen University 83 S. : Ill., graph. Darst. (2003). = Aachen, Techn. Hochsch., Diss., 2003"],"dc:subject":["info:eu-repo/classification/ddc/610","Medizin","b2-Mikroglobulin","Amyloidose","Dialysemembranen","Hämodialyse"],"dc:title":["Zum Einfluß von Dialysemembranmaterialien auf den [beta]-2-Mikroglobulinspiegel unter Hämodialyse"],"dc:type":["info:eu-repo/semantics/doctoralThesis","info:eu-repo/semantics/publishedVersion"]},"updated_at":"2026-07-30T19:42:39Z"}